Positron Emission Tomography (PET) and PET/CT in Thyroid Cancer: A Systematic Review and Meta-Analysis
Open Access
- 24 October 2017
- journal article
- review article
- Published by Bioscientifica in European Thyroid Journal
- Vol. 7 (1) , 13-20
Abstract
Background: Positron emission tomography (PET) and PET/CT are functional imaging methods that are widely used in diagnostic procedures in oncology. Objectives: The objective of this study was to assess the patient-relevant benefit of PET or PET/CT in patients with thyroid cancer based on a literature review and meta-analysis. Methods: A systematic review including studies that had been published until December 2013 was performed. To be included, studies had to prospectively investigate patients with thyroid cancer in a clinical setting of staging, restaging, or diagnosing tumour recurrence. Results: Out of 3,506 potentially relevant articles, 29 studies were included. No study directly evaluated the benefits of PET. Twenty-eight studies dealt with the diagnostic accuracy of PET or PET/CT, and 1 study evaluated the prognostic value of PET/CT. The authors showed that a positive result of PET/CT in restaging patients with differentiated thyroid cancer yielded a significant decrease in overall survival (hazard ratio, HR 5.01, CI 3.41–6.62). In patients with suspected recurrence of differentiated thyroid cancer, meta-analysis showed higher sensitivity of PET (89.7%, CI 78–99%) and PET/CT (94.3%, CI 87–97%) compared with conventional imaging (65.4%, CI 32–88%) and comparable results for specificity. Due to the low numbers of studies and patients, meta-analyses on medullary carcinoma did not produce meaningful results. Conclusion: The patient-relevant benefits of PET or PET/CT in thyroid cancer could not be evaluated satisfactorily based on the included studies. It remains unclear whether higher diagnostic test accuracy leads to changes in therapeutic strategies and better patient-relevant outcomes.Keywords
This publication has 50 references indexed in Scilit:
- Clinical value of technetium-99m-labeled octreotide scintigraphy in local recurrent or metastatic medullary thyroid cancersNuclear Medicine Communications, 2013
- Prognostic Significance of FDG PET/CT on the Follow-Up of Patients of Differentiated Thyroid Carcinoma With Negative 131I Whole-Body Scan and Elevated Thyroglobulin LevelsClinical Nuclear Medicine, 2012
- Correlation between Calcitonin Levels and []FDG-PET/CT in the Detection of Recurrence in Patients with Sporadic and Hereditary Medullary Thyroid CancerISRN Endocrinology, 2012
- 18F‐FDG‐PET and 18F‐FDG‐PET/CT in the detection of recurrent or metastatic medullary thyroid carcinoma: A systematic review and meta‐analysisJournal of Medical Imaging and Radiation Oncology, 2012
- Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III TrialJournal of Clinical Oncology, 2012
- Complementary Roles of 18F-DOPA PET/CT and 18F-FDG PET/CT in Medullary Thyroid CancerJournal of Nuclear Medicine, 2011
- Phase II Study of Daily Sunitinib in FDG-PET–Positive, Iodine-Refractory Differentiated Thyroid Cancer and Metastatic Medullary Carcinoma of the Thyroid with Functional Imaging CorrelationClinical Cancer Research, 2010
- The role of 18F-FDG PET/CT in detecting metastatic deposits of recurrent medullary thyroid carcinoma: A prospective studyEuropean Journal of Surgical Oncology, 2008
- Therapeutic impact of 18FDG-PET/CT in the management of iodine-negative recurrence of differentiated thyroid carcinomaSurgery, 2007
- Valor diagnóstico da tomografia por emissão de pósitrons / tomografia computadorizada (PET-CT) com flúor-18 fluordeoxiglicose (FDG-18F) em pacientes com carcinoma diferenciado da tireóide, níveis séricos de tireoglobulina elevados e pesquisa de corpo inteiro com iodo negativaArchives of Endocrinology and Metabolism, 2007